Smurfit Westrock has opened a new €40 million clinical packaging facility near Dublin Airport, establishing what the company describes as the world’s first site dedicated exclusively to adherence and clinical-trial packaging.
The investment reflects the growing importance of packaging solutions that support patient compliance and regulatory standards in healthcare.
The Adherence & Clinicals plant will provide packaging tailored for clinical trials and regulated pharmaceutical use. Designed and operated to pharmaceutical manufacturing standards, the facility places a strong emphasis on patient safety and usability throughout its processes.
Highlighting the facility’s purpose, Tony Smurfit, President and CEO of Smurfit Westrock, said, “The packaging solutions developed here will play a role in supporting the next generation of medicines.”
The Dublin site employs around 170 people, including designers, operators, and support staff. It also features an Experience Centre where customers collaborate on packaging designs developed to meet the specific requirements of clinical studies.
According to the company, packaging plays a vital role in improving patient adherence and ensuring the accurate collection of clinical data. Through this facility, Smurfit Westrock aims to deliver consistent, high-quality packaging that supports the complex demands of pharmaceutical manufacturers and clinical organizations.
Strategically located to serve the European market, the Dublin plant complements Smurfit Westrock’s existing clinical packaging operations in Kunshan, China, and Mebane, North Carolina.
Smurfit Westrock is a global leader in sustainable paper and packaging solutions, combining the expertise of Smurfit Kappa and WestRock. The company operates in more than 40 countries, producing renewable, fiber-based packaging designed to advance circularity and reduce environmental impact.
